Analyzing Kamada (NASDAQ:KMDA) and Ionis Pharmaceuticals (NASDAQ:IONS)

Ionis Pharmaceuticals (NASDAQ:IONS – Get Free Report) and Kamada (NASDAQ:KMDA – Get Free Report) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, valuation, analyst recommendations and dividends.

Volatility & Risk

Ionis Pharmaceuticals has a beta of 0.43, indicating that its share price is 57% less volatile than the S&P 500. Comparatively, Kamada has a beta of 0.9, indicating that its share price is 10% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings for Ionis Pharmaceuticals and Kamada, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ionis Pharmaceuticals 1 3 19 0 2.78
Kamada 0 0 4 0 3.00

Ionis Pharmaceuticals currently has a consensus target price of $75.00, indicating a potential upside of 182.14%. Kamada has a consensus target price of $13.75, indicating a potential upside of 77.65%. Given Ionis Pharmaceuticals’ higher probable upside, analysts clearly believe Ionis Pharmaceuticals is more favorable than Kamada.

Profitability

This table compares Ionis Pharmaceuticals and Kamada’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Ionis Pharmaceuticals -56.98% -120.62% -16.99%
Kamada 12.67% 9.36% 6.53%

Insider and Institutional Ownership

93.9% of Ionis Pharmaceuticals shares are owned by institutional investors. Comparatively, 20.4% of Kamada shares are owned by institutional investors. 1.8% of Ionis Pharmaceuticals shares are owned by company insiders. Comparatively, 36.1% of Kamada shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Ionis Pharmaceuticals and Kamada”s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Ionis Pharmaceuticals $944.00 million 4.69 -$381.39 million ($3.32) -8.01
Kamada $180.46 million 2.47 $20.20 million $0.43 18.00

Kamada has lower revenue, but higher earnings than Ionis Pharmaceuticals. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks.

Summary

Kamada beats Ionis Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

About Ionis Pharmaceuticals

(Get Free Report)

Ionis Pharmaceuticals is a biotechnology company that discovers and develops RNA-targeted medicines, with a focus on antisense oligonucleotides. Its medicines are designed to act on RNA and change the production of proteins linked to disease. The company’s research and development programs span neurological, cardiovascular, metabolic and rare diseases. Ionis has developed medicines that it commercializes itself and products advanced or marketed with pharmaceutical partners. Its medicines and partnered products include treatments for conditions such as spinal muscular atrophy and transthyretin amyloidosis.

About Kamada

(Get Free Report)

Kamada Ltd. is an Israeli biopharmaceutical company that develops, manufactures and markets plasma-derived therapies and specialty pharmaceutical products. Founded in 1990, the company is headquartered in Rehovot, Israel. Its products include Glassia, an alpha-1 proteinase inhibitor used to treat people with alpha-1 antitrypsin deficiency, and immune globulin therapies for conditions including rabies exposure, cytomegalovirus infection and varicella-zoster exposure. Kamada serves markets in the United States and internationally, selling products directly and through commercial partners.

Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.